HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

466.050

+2.3470.51%

Number of Gainers:49

Number of Losers:3

Number of Flat:3

PE:- -

High:466.181

Open:456.548

Low:453.721

Close:463.703

Loading ...

BRIEF-HBM Holdings Intends To Repurchase Shares Of Co

Hbm Holdings - Intends to Repurchase Shares of Co in Open Market From Time to Time up to HK$200 Mln

THOMSON REUTERS

Peijia Medical Gets China Nod for Registration of YonFlow Stent

MT Newswires Live

BUZZ-HK-listed Simcere Pharmaceutical gains on clinical trial approval for cancer drug

China Tower Corporation Limited's (HKG:788) stock price dropped 4.7% last week; private companies would not be happy

Simply Wall St.

Simcere Pharma Gets China Clinical Trial Nod for Anti-Tumor Drug; Shares Rise 3%

MT Newswires Live

Harbour Biomed Appoints Youchen Chen as Chief Financial Officer

THOMSON REUTERS

BRIEF-Simcere Pharmaceutical Says Clinical Trial Approval For SIM0686 Issued By NMPA

Simcere Pharmaceutical - Clinical Trial Approval for Sim0686 Issued by Nmpa

THOMSON REUTERS

BRIEF-Peijia Medical Gets NMPA Approval For Registration Application Of Stent

Peijia Medical - Nmpa Approval for Registration Application of Yonflow Flow Diverting Stent

THOMSON REUTERS

Hong Kong Stocks Reverse Early Losses to End Higher; Pharma Stocks Slide

MT Newswires Live

WuXi AppTec Proposes 1 Billion Yuan A Share Buyback

MT Newswires Live

Hong Kong Pharma Stocks Decline as Trump Threatens Tariffs on Imported Drugs

MT Newswires Live

Hong Kong Shares of WuXi AppTec Down 7%

THOMSON REUTERS

Hansoh Pharmaceutical Gets China Nod for Trial of Two Tumor Drugs

MT Newswires Live

Conch Cement Forecasts 20% Rise in Q1 Attributable Profit

MT Newswires Live

Luye Pharma Gets Macao Approval for Antidepressant

MT Newswires Live

Antengene to Buy Back Up to HK$40 Million of Shares

MT Newswires Live

The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1583/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":466.05002,"timestamp":1745302539088,"preClose":463.70267,"halted":0,"volume":573734067,"delay":0,"changeRate":0.005062,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":2.347351,"latestTime":"04-22 14:15:39","open":456.54776,"high":466.181,"low":453.7205,"amount":17518743893,"amplitude":0.026872,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745309400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"pbRate":2.20563,"peRate":21.792246,"turnoverRate":0.00417,"increases":49,"decrements":3,"flats":2,"marketCap":2614433117056,"floatMarketCap":2063412284544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":466.181,"amplitude":0.026872,"preClose":463.70267,"low":453.7205,"pbRate":"2.20563","latestPrice":466.05002,"volume":573734067,"delay":0,"open":456.54776,"prevYearClose":446.93042,"prevWeekClose":463.703,"prevMonthClose":505.776,"prevQuarterClose":505.776,"fiveDayClose":474.257,"twentyDayClose":518.706,"sixtyDayClose":450.103,"secType":"PLATE","market":"HK","turnoverRate":0.00417,"peRate":21.792246,"marketCap":2614433117056,"floatMarketCap":2063412284544,"timestamp":1745302539088,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":49,"down":3,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526597191","title":"BRIEF-HBM Holdings Intends To Repurchase Shares Of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2526597191","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526597191?lang=en_us&edition=fundamental","pubTime":"2025-04-10 23:33","pubTimestamp":1744299194,"startTime":"0","endTime":"0","summary":"BRIEF-HBM Holdings Intends To Repurchase Shares Of CoApril 10 (Reuters) - Hbm Holdings Ltd 2142.HK:INTENDS TO REPURCHASE SHARES OF CO IN OPEN MARKET FROM TIME TO TIME UP TO HK$200 MILLIONFurther company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","02142","BK1574"],"gpt_icon":0},{"id":"2526556200","title":"Hbm Holdings -  Intends to Repurchase Shares of Co in Open Market From Time to Time up to HK$200 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2526556200","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526556200?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:29","pubTimestamp":1744291797,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"2526559026","title":"Peijia Medical Gets China Nod for Registration of YonFlow Stent","url":"https://stock-news.laohu8.com/highlight/detail?id=2526559026","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526559026?lang=en_us&edition=fundamental","pubTime":"2025-04-10 18:53","pubTimestamp":1744282385,"startTime":"0","endTime":"0","summary":"Peijia Medical  obtained registration approval for the YonFlow Flow Diverting Stent from China's National Medical Products Administration, a Wednesday filing with the Hong Kong bourse said.YonFlow Flow Diverting Stent has been developed by Jiangsu NowYon Medical.Peijia Medical entered into an exclusive distribution agreement with NowYon Medical in August 2024 to sell and distribute the product in Greater China.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","09996","BK1100","BK1574"],"gpt_icon":0},{"id":"2526067163","title":"BUZZ-HK-listed Simcere Pharmaceutical gains on clinical trial approval for cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2526067163","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526067163?lang=en_us&edition=fundamental","pubTime":"2025-04-10 13:09","pubTimestamp":1744261791,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Simcere Pharmaceutical gains on clinical trial approval for cancer drug ** Shares of Simcere Pharmaceutical Group Ltd 2096.HK jump 5.5% to HK$8.07, their biggest intraday pct gain since February 18** Stock on course for a third consecutive session of gains, if current trend holds ** Simcere Pharmaceutical says its anti-tumor drug candidate - SIM0686 - has obtained a Clinical Trial Approval, issued by China's National Medical Products Administration ** SIM0686 is an FGFR2b Antibody-Drug Conjugate for treatment of gastric cancer and lung cancer** Hong Kong's healthcare index .HSCIH rises 2.1%, Hang Seng Index .HSI rises 1.8%** Stock up 7.8% YTD    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nL2N3QO05D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","02096"],"gpt_icon":0},{"id":"2526755832","title":"China Tower Corporation Limited's (HKG:788) stock price dropped 4.7% last week; private companies would not be happy","url":"https://stock-news.laohu8.com/highlight/detail?id=2526755832","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526755832?lang=en_us&edition=fundamental","pubTime":"2025-04-10 12:41","pubTimestamp":1744260098,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by private companies in China Tower indicates that they collectively have a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/telecom/hkg-788/china-tower-shares/news/china-tower-corporation-limiteds-hkg788-stock-price-dropped-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0823413660.USD","LU0823413587.USD","BK1133","BK1529","00788","IE00BHRH8C09.USD","IE00BHRH8D16.HKD","BK1521","BK1583","BK1506","BK1589","IE00BG0RBZ43.SGD"],"gpt_icon":0},{"id":"2526377011","title":"Simcere Pharma Gets China Clinical Trial Nod for Anti-Tumor Drug; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526377011","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526377011?lang=en_us&edition=fundamental","pubTime":"2025-04-10 11:41","pubTimestamp":1744256462,"startTime":"0","endTime":"0","summary":"China's medical products administrator approved Simcere Pharmaceutical's  clinical trial application for the SIM0686 drug for tumors, according to a Thursday filing with the Hong Kong bourse.SIM0686 is intended for the treatment of advanced malignant tumors such as gastric and lung cancer, the filing said.Shares jumped 3% during Thursday's morning trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1583","02096"],"gpt_icon":0},{"id":"2526637338","title":"Harbour Biomed Appoints Youchen Chen as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526637338","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526637338?lang=en_us&edition=fundamental","pubTime":"2025-04-10 10:00","pubTimestamp":1744250405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA6Z4B35:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2526322592","title":"BRIEF-Simcere Pharmaceutical Says Clinical Trial Approval For SIM0686 Issued By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2526322592","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526322592?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:27","pubTimestamp":1744248444,"startTime":"0","endTime":"0","summary":"BRIEF-Simcere Pharmaceutical Says Clinical Trial Approval For SIM0686 Issued By NMPAApril 10 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK:CLINICAL TRIAL APPROVAL FOR SIM0686 ISSUED BY NMPASource text: ID:nHKSbmp9jBFurther company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN23E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","BK1583","BK1191"],"gpt_icon":0},{"id":"2526323659","title":"Simcere Pharmaceutical - Clinical Trial Approval for Sim0686 Issued by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2526323659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526323659?lang=en_us&edition=fundamental","pubTime":"2025-04-10 08:00","pubTimestamp":1744243248,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN23E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02096","BK1191","BK1583"],"gpt_icon":0},{"id":"2526839941","title":"BRIEF-Peijia Medical Gets NMPA Approval For Registration Application Of Stent","url":"https://stock-news.laohu8.com/highlight/detail?id=2526839941","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526839941?lang=en_us&edition=fundamental","pubTime":"2025-04-09 23:27","pubTimestamp":1744212434,"startTime":"0","endTime":"0","summary":"BRIEF-Peijia Medical Gets NMPA Approval For Registration Application Of StentApril 9 (Reuters) - Peijia Medical Ltd 9996.HK:NMPA APPROVAL FOR REGISTRATION APPLICATION OF YONFLOW FLOW DIVERTING STENTFurther company coverage: 9996.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM25R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","BK1574","BK1583","BK1100"],"gpt_icon":0},{"id":"2526351380","title":"Peijia Medical - Nmpa Approval for Registration Application of Yonflow Flow Diverting Stent","url":"https://stock-news.laohu8.com/highlight/detail?id=2526351380","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526351380?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:41","pubTimestamp":1744195313,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM25R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09996","BK1574","BK1583","BK1100"],"gpt_icon":0},{"id":"2526378903","title":"Hong Kong Stocks Reverse Early Losses to End Higher; Pharma Stocks Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2526378903","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526378903?lang=en_us&edition=fundamental","pubTime":"2025-04-09 17:18","pubTimestamp":1744190288,"startTime":"0","endTime":"0","summary":"Hong Kong stocks reversed earlier losses to finish moderately higher on Wednesday, as sentiment improved on hopes that China will roll out fresh measures to shield the economy from US tariffs.The Hang","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1588","HK0000320223.HKD","HSI","LU1969619763.USD","02186","02833","09688","BK1576","LU0307460666.USD","BK1161","HK0000306701.USD","BK1500","LU2328871848.SGD","BK1574","HHImain","BK1191","513600","HK0000320264.USD","LU0588546209.SGD","HK0000306685.HKD","06955","BK1141","LU2488822045.USD","BK1606","06160","MCHmain","09966","01548","BK1583"],"gpt_icon":0},{"id":"2526315333","title":"WuXi AppTec Proposes 1 Billion Yuan A Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2526315333","media":"MT Newswires Live","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526315333?lang=en_us&edition=fundamental","pubTime":"2025-04-09 16:57","pubTimestamp":1744189078,"startTime":"0","endTime":"0","summary":"WuXi AppTec  has proposed a buyback plan to repurchase up to 1 billion yuan worth of A shares through bidding on the Shanghai Stock Exchange,Around up to 10,283,833 A shares are expected to be bought back within a period of three months following board approval.The shares represent 0.3561% of the firm's issued share capital as of Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0052750758.USD","LU0708995583.HKD","BK1141","LU2125910500.SGD","02359","LU1997245177.USD","BK1583","LU1046422090.SGD","LU2045819591.USD","BK1576","603259","BK0216","LU0456842615.SGD","LU2242644610.SGD","LU1997245094.SGD","LU2488822045.USD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2526996382","title":"Hong Kong Pharma Stocks Decline as Trump Threatens Tariffs on Imported Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2526996382","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526996382?lang=en_us&edition=fundamental","pubTime":"2025-04-09 15:25","pubTimestamp":1744183543,"startTime":"0","endTime":"0","summary":"Hong Kong pharmaceutical stocks fell on Wednesday after US President Donald Trump said his administration would soon implement \"a major tariff on pharmaceuticals\" from foreign nations.Trump made the remarks at a Republican event, suggesting the move will force drug companies to relocate their operations to the US, according to a USA Today report.While initially sparing pharmaceuticals from recent tariffs, Trump has indicated for months that the imported drug industry is a future target, the report said.The news sent shares of Hong Kong-listed drugmakers falling on Wednesday afternoon.Alphamab Oncology  led the decliners with an almost 6% fall, followed by Boan Biotech  with a 5% drop. Luye Pharma  slid 4.4%, while BeiGene  and Genscript Bio  retreated nearly 4%. Zai Lab  slipped 3%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000306701.USD","LU1969619763.USD","HK0000320223.HKD","BK1500","01548","BK1191","BK1588","BK1574","BK1141","BK1606","BK1583","09688","06955","BK1576","LU0588546209.SGD","LU2328871848.SGD","BK1161","LU2488822045.USD","09966","HK0000306685.HKD","LU0307460666.USD","02186","HK0000320264.USD","06160"],"gpt_icon":0},{"id":"2526879090","title":"Hong Kong Shares of WuXi AppTec  Down 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526879090","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526879090?lang=en_us&edition=fundamental","pubTime":"2025-04-09 09:35","pubTimestamp":1744162507,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nL3N3QN04O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2242644610.SGD","LU0708995583.HKD","02359","LU1046422090.SGD","LU2125910500.SGD","BK1583","LU1997245094.SGD","LU2045819591.USD","LU2488822045.USD","LU0052750758.USD","BK1576","LU0456842615.SGD","LU0320764599.SGD","LU1997245177.USD","603259","BK1141","BK0216"],"gpt_icon":0},{"id":"2525897757","title":"Hansoh Pharmaceutical Gets China Nod for Trial of Two Tumor Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2525897757","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525897757?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:14","pubTimestamp":1744118056,"startTime":"0","endTime":"0","summary":"Two products of Hansoh Pharmaceutical Group  have received clinical trial approval from China's National Medical Products Administration, two filings with the Hong Kong bourse on Monday said.Both drugs will be tested for the treatment of advanced solid tumors, according to the pharmaceutical company.HS-20122 for injection will be investigated for tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, or colorectal cancer. HS-20108 for injection will be tested for the treatment of small cell lung cancer and neuroendocrine tumors.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1583","BK1589","03692"],"gpt_icon":0},{"id":"2525957048","title":"Conch Cement Forecasts 20% Rise in Q1 Attributable Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2525957048","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525957048?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:42","pubTimestamp":1744112536,"startTime":"0","endTime":"0","summary":"Anhui Conch Cement  forecasts its attributable profit will rise about 20% to 1.81 billion yuan in the first quarter from 1.50 billion yuan in the year-ago period.The cement manufacturer attributes the upbeat forecast to higher sales volume and lower product costs, according to a Tuesday filing with the Hong Kong bourse.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK1505","BK0183","BK0196","BK1594","BK1583","BK1135","BK0044","LU1328615791.USD","BK0012","BK1563","BK0187","600585","BK0235","BK1507","00914","BK0188","BK0015"],"gpt_icon":0},{"id":"2525889522","title":"Luye Pharma Gets Macao Approval for Antidepressant","url":"https://stock-news.laohu8.com/highlight/detail?id=2525889522","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525889522?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:40","pubTimestamp":1744112444,"startTime":"0","endTime":"0","summary":"Luye Pharma  secured Macao government's approval to market toludesvenlafaxine hydrochloride extended-release tablets, according to a Monday filing with the Hong Kong bourse.The drug, branded Ruoxinlin, is indicated for major depressive disorder, the filing said.Phase 3 study results showed the drug reduces anxiety, retardation, fatigue, and anhedonia or lack of interest, promotes social functions, and improves cognition, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1606","BK1583","BK1191","02186"],"gpt_icon":0},{"id":"2525832279","title":"Antengene to Buy Back Up to HK$40 Million of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2525832279","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525832279?lang=en_us&edition=fundamental","pubTime":"2025-04-08 14:39","pubTimestamp":1744094341,"startTime":"0","endTime":"0","summary":"Antengene  will buy back up to 67,488,874 shares, or 10% of the entire shareholding of the drug company, according to a Tuesday filing with the Hong Kong bourse.The maximum aggregate price for the share repurchase is HK$40 million, the filing said.Antengene's shares rose 1% during Tuesday's afternoon trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06996","BK1191","BK1574","BK1583"],"gpt_icon":0},{"id":"2525852117","title":"The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2525852117","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525852117?lang=en_us&edition=fundamental","pubTime":"2025-04-08 12:57","pubTimestamp":1744088241,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited ( HKG:1952 ) shareholders won't be pleased to see that the share price has had a very rough...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/the-price-is-right-for-everest-medicines-limited-hkg1952-eve","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","01952","BK1583","MDCO"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":70,"code":"91000000","status":"200"}]}}